Suzanne Kyle

TL;DR: It is proposed that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair and exploited in order to kill BRCA2-deficient tumours by PARP inhibition alone.

TL;DR: HR status can be determined in primary cancer samples by Rad51 focus formation, and this correlates with in vitro response to PARP inhibition, and use of this assay as a biomarker now needs testing in the setting of a clinical trial.

TL;DR: NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors and provides proof of concept data for clinical development of ATR inhibitors.

TL;DR: KU59403 provides the first proof-of-principle preclinical data to support the future clinical development of ATM inhibitors, being the first compound to show good tissue distribution and significant chemosensitization in in vivo models of human cancer, without major toxicity.

TL;DR: There was an excellent correlation between the concentration-dependence and exposure time of wortmannin required to enhance IR cytotoxicity and inhibit DSB repair, which implicate inhibition of DNA-dependent protein kinase, and the consequent inhibition of D SB repair, as the mechanism whereby wortmanin potentiates the cytot toxicity of IR.